PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för Ro 25-6981. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

29 hits

Bibliografisk träff 2021-09-16

The GluN2B-Selective Antagonist Ro 25-6981 Is Effective against PTZ-Induced Seizures and Safe for Further Development in Infantile Rats.

Mareš P, Kozlová L, Mikulecká A, Kubová H.

Pharmaceutics · research-article; journal article · DOI 10.3390/pharmaceutics13091482

Bibliografisk träff 2021-08-25

Prevention of glutamate excitotoxicity in lateral habenula alleviates ethanol withdrawal-induced somatic and behavioral effects in ethanol dependent mice.

Gakare SG, Varghese SS, Patni PP, Wagh SA, Ugale RR.

Behav Brain Res · journal article · DOI 10.1016/j.bbr.2021.113557

Bibliografisk träff 2021-08-07

Structural connectivity and subcellular changes after antidepressant doses of ketamine and Ro 25-6981 in the rat: an MRI and immuno-labeling study.

Pascual-Antón R, Blasco-Serra A, Muñoz-Moreno E, Pilar-Cuéllar F, Garro-Martínez E, Florensa-Zanuy E, López-Gil X, Campa VM, Soria G, Adell A.

Brain Struct Funct · research-article; journal article · DOI 10.1007/s00429-021-02354-0

Bibliografisk träff 2020-12-01

Effects of the GluN2B antagonist, Ro 25-6981, on extinction consolidation following adolescent- or adult-onset methamphetamine self-administration in male and female rats.

Westbrook SR, Gulley JM.

Behav Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1097/fbp.0000000000000586

Bibliografisk träff 2020-07-06

Ketamine and Ro 25-6981 Reverse Behavioral Abnormalities in Rats Subjected to Dietary Zinc Restriction.

Pochwat B, Domin H, Rafało-Ulińska A, Szewczyk B, Nowak G.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms21134791

Bibliografisk träff 2018-07-02

Injecting NMDA and Ro 25-6981 in insular cortex induce neuroplastic changes and neuropathic pain-like behaviour.

Yoon MS, Koh CS, Lee J, Shin J, Kong C, Jung HH, Chang JW.

Eur J Pain · research support, non-u.s. gov't; journal article · DOI 10.1002/ejp.1254

Bibliografisk träff 2018-05-22

The Neurogenesis Actuator and NR2B/NMDA Receptor Antagonist Ro25-6981 Consistently Improves Spatial Memory Retraining Via Brain Region-Specific Gene Expression.

Gruden MA, Ratmirov AM, Storozheva ZI, Solovieva OA, Sherstnev VV, Sewell RDE.

J Mol Neurosci · research-article; journal article · DOI 10.1007/s12031-018-1083-5

Bibliografisk träff 2018-05-22

Biopharmaceutical Characterization and Oral Efficacy of a New Rapid Acting Antidepressant Ro 25-6981.

Yellepeddi VK, Zhudeva MY, Movahedi F, Vo A, Phan J, Kirsh RD, Rawlins DB, Talbot JN.

J Pharm Sci · journal article · DOI 10.1016/j.xphs.2018.05.005

Bibliografisk träff 2018-05-18

N-methyl D-aspartate receptor subtype 2B antagonist, Ro 25-6981, attenuates neuropathic pain by inhibiting postsynaptic density 95 expression.

Huang LE, Guo SH, Thitiseranee L, Yang Y, Zhou YF, Yao YX.

Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41598-018-26209-7

Bibliografisk träff 2017-08-09

Involvement of extracellular signal-regulated kinase (ERK) in the short and long-lasting antidepressant-like activity of NMDA receptor antagonists (zinc and Ro 25-6981) in the forced swim test in rats.

Pochwat B, Rafało-Ulińska A, Domin H, Misztak P, Nowak G, Szewczyk B.

Neuropharmacology · journal article · DOI 10.1016/j.neuropharm.2017.08.006

Bibliografisk träff 2016-11-18

Effects of the GluN2B-NMDA receptor antagonist Ro 25-6981 on two types of behavioral flexibility in rats.

Clark E, Antoniak K, Feniquito A, Dringenberg HC.

Behav Brain Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbr.2016.11.032

Bibliografisk träff 2016-07-25

Neuroprotection of Ro25-6981 Against Ischemia/Reperfusion-Induced Brain Injury via Inhibition of Autophagy.

Dong F, Yao R, Yu H, Liu Y.

Cell Mol Neurobiol · research-article; journal article · DOI 10.1007/s10571-016-0409-5

Bibliografisk träff 2016-04-07

Mechanism of NMDA Receptor Inhibition and Activation.

Zhu S, Stein RA, Yoshioka C, Lee CH, Goehring A, Mchaourab HS, Gouaux E.

Cell · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.cell.2016.03.028

Bibliografisk träff 2014-11-11

Different action of a specific NR2B/NMDA antagonist Ro 25-6981 on cortical evoked potentials and epileptic afterdischarges in immature rats.

Szczurowska E, Mareš P.

Brain Res Bull · research support, non-u.s. gov't; journal article · DOI 10.1016/j.brainresbull.2014.11.001

Bibliografisk träff 2014-06-22

NMDA receptor structures reveal subunit arrangement and pore architecture.

Lee CH, Lü W, Michel JC, Goehring A, Du J, Song X, Gouaux E.

Nature · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/nature13548

Bibliografisk träff 2014-06-03

NMDA receptor antagonists ketamine and Ro25-6981 inhibit evoked release of glutamate in vivo in the subiculum.

Stan TL, Alvarsson A, Branzell N, Sousa VC, Svenningsson P.

Transl Psychiatry · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/tp.2014.39

Bibliografisk träff 2013-09-27

Antinociception and prevention of hyperalgesia by intrathecal administration of Ro 25-6981, a highly selective antagonist of the 2B subunit of N-methyl-D-aspartate receptor.

Jiang M, Zhang W, Ma Z, Gu X.

Pharmacol Biochem Behav · research support, non-u.s. gov't; journal article · DOI 10.1016/j.pbb.2013.09.007

Bibliografisk träff 2012-09-01

Neurogenesis enhancer RO 25-6981 facilitates repeated spatial learning in adult rats.

Soloviova OA, Proshin AT, Storozheva ZI, Sherstnev VV.

Bull Exp Biol Med · journal article · DOI 10.1007/s10517-012-1821-6

Bibliografisk träff 2011-06-15

Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors.

Karakas E, Simorowski N, Furukawa H.

Nature · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/nature10180

Bibliografisk träff 2011-02-01

[Effects of the neurogenesis stimulator Ro 25-6981 upon formation of spatial skill in adult rats depend on the term of its administration and the animals' ability to learn].

Solov'eva OA, Storozheva ZI, Proshin AT, Sherstnev VV.

Ross Fiziol Zh Im I M Sechenova · journal article; english abstract

Bibliografisk träff 2008-09-08

Fear memory impairing effects of systemic treatment with the NMDA NR2B subunit antagonist, Ro 25-6981, in mice: attenuation with ageing.

Mathur P, Graybeal C, Feyder M, Davis MI, Holmes A.

Pharmacol Biochem Behav · research support, n.i.h., intramural; research-article; journal article · DOI 10.1016/j.pbb.2008.08.028

Bibliografisk träff 2007-10-25

Spinal cord long-term potentiation is attenuated by the NMDA-2B receptor antagonist Ro 25-6981.

Pedersen LM, Gjerstad J.

Acta Physiol (Oxf) · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1748-1716.2007.01756.x

Bibliografisk träff 2004-07-15

The NR2B-selective N-methyl-D-aspartate receptor antagonist Ro 25-6981 [(+/-)-(R,S)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine propanol] potentiates the effect of nicotine on locomotor activity and dopamine release in the nucleus accumbens.

Kosowski AR, Liljequist S.

J Pharmacol Exp Ther · research support, non-u.s. gov't; journal article · DOI 10.1124/jpet.104.070235

Bibliografisk träff 2004-05-01

Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.

Löschmann PA, De Groote C, Smith L, Wüllner U, Fischer G, Kemp JA, Jenner P, Klockgether T.

Exp Neurol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.expneurol.2004.01.018

Bibliografisk träff 2003-10-08

Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket.

Malherbe P, Mutel V, Broger C, Perin-Dureau F, Kemp JA, Neyton J, Paoletti P, Kew JN.

J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.103.056291

Bibliografisk träff 2003-01-01

The NMDA receptor NR2B subtype selective antagonist Ro 25-6981 aggravates paroxysmal dyskinesia in the dt(sz) mutant.

Richter A.

Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/s0014-2999(02)02765-6

Bibliografisk träff 2001-03-01

Pharmacological characterization of interactions of RO 25-6981 with the NR2B (epsilon2) subunit.

Lynch DR, Shim SS, Seifert KM, Kurapathi S, Mutel V, Gallagher MJ, Guttmann RP.

Eur J Pharmacol · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1016/s0014-2999(01)00868-8

Bibliografisk träff 1998-05-01

In vitro binding properties in rat brain of [3H]Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits.

Mutel V, Buchy D, Klingelschmidt A, Messer J, Bleuel Z, Kemp JA, Richards JG.

J Neurochem · journal article · DOI 10.1046/j.1471-4159.1998.70052147.x

Bibliografisk träff 1997-12-01

Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro.

Fischer G, Mutel V, Trube G, Malherbe P, Kew JN, Mohacsi E, Heitz MP, Kemp JA.

J Pharmacol Exp Ther · journal article · DOI 10.1016/s0022-3565(24)37138-1